Moran Jay, Miller Mark D, Schneble Christopher A, Yalcin Sercan, Katz Lee D, Medvecky Michael J
Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, Connecticut.
Division of Sports Medicine, Department of Orthopaedic Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.
JBJS Essent Surg Tech. 2022 Mar 21;12(1). doi: 10.2106/JBJS.ST.21.00051. eCollection 2022 Jan-Mar.
Tenosynovial giant cell tumor (T-GCT) and pigmented villonodular synovitis (PVNS) are interchangeable terms for an uncommon benign proliferation of synovial tissue. Although neoplastic and inflammatory origins have been hypothesized, the etiology of this condition is unknown. There is controversy regarding surgical treatment, as the open and arthroscopic approaches to synovectomy have shown comparable reported outcomes in the literature. However, direct comparison of these 2 operative methods is problematic because of selective bias in the existing literature and the lack of any prospective, randomized controlled trials. In the posterior aspect of the knee, arthroscopic synovectomy is technically challenging because of anatomical blind spots when viewing this space from an anterior portal in a trans-notch fashion. Additionally, incomplete arthroscopic synovectomies increase PVNS recurrence rates, making it imperative to remove the entire lesion. The trans-septal portal (TSP) technique utilizes both posteromedial and posterolateral portals to create an intra-articular portal through the posterior septum that separates the 2 posterior compartments of the knee. This portal allows working instruments to be passed back-and-forth across the posterior septum and increases the visualization of both the posterosuperior synovial lining of the condyles and the synovial reflection behind the posterior cruciate ligament, enabling a thorough assessment for arthroscopic PVNS resection. In this video article, we describe a posterior arthroscopic synovectomy with use of a TSP for PVNS within the posterior compartment of the knee.
The patient is positioned such that the contralateral leg will not obstruct the ability to work in the posteromedial portal. Diagnostic arthroscopy is performed through standard anteromedial and anterolateral portals. Next, with visualization from the anterolateral portal and the knee in 90° of flexion, the posteromedial portal is created with use of a transilluminated spinal needle. The posterolateral portal is made in the same fashion as the posteromedial portal, with use of a trans-notch view from the anteromedial portal. With the arthroscope in the posteromedial portal, a blunt instrument or motorized shaver can be placed through the posterolateral portal to perforate the posterior septum and create the TSP. The mass can then be identified, biopsied, and removed with use of a motorized shaver or tissue grasper. Arthroscopic exploration through the TSP can then be done to confirm adequate excision.
Alternatives include synovectomy either by arthrotomy, arthroscopy via a posteromedial or posterolateral portal with trans-notch views, or a combination of both. To limit the risk of recurrent diffuse PVNS, radiosynovectomy with yttrium-90 or phosphorus-32, either combined with surgery or alone, has been described. External beam radiation has also been utilized, but radiation toxicity is seen as a major limitation. Macrophage-colony stimulating factor (M-CSF) or CSF-1 inhibitors have recently been developed. In 2019, the FDA approved the use of CSF-1 inhibitors, and they are considered an acceptable treatment for patients who are not candidates for surgical resection.
Advantages involve increased posterior anatomy visualization to ensure adequate synovectomy, more working capacity for instruments, and decreased disruption of anatomical planes and scar tissue formation around neurovascular structures compared with open dissection.
Excellent clinical results (defined by return to full knee function) have been reported for the TSP technique for PVNS synovectomy. In a study of 10 cases of posterior-knee PVNS masses removed via arthroscopic synovectomy with use of a TSP, Shekhar et al. reported good functional outcomes and no operative complications. Keyhani et al. reported a series of 21 patients who underwent the same procedure for diffuse PVNS with similar findings. Patients can expect to retain close to full knee function following this procedure. Baseline magnetic resonance imaging is recommended for all patients at 3 to 6 months after excision, as asymptomatic recurrence can occur, and patients should be followed for a minimum of 2 years post-excision.
Keeping the knee in 90° of flexion provides the furthest distance from the saphenous vein on the medial side, the peroneal nerve on the lateral side, and the popliteal artery near the posterior septum when making the posterior portals.Transillumination of the posterior portals is recommended.Perforation of the septum should be in the posterolateral to posteromedial direction, allowing surgeons to have a wider "safe zone" to decrease the chance of vascular injury to the popliteal artery.
CSF = colony-stimulating factorMCL = medial collateral ligamentMRI = magnetic resonance imagingPL = posterolateralPM = posteromedialPA = popliteal arteryROM = range of motionTS = trans-septalIKDC = International Knee Documentation Committee.
腱鞘巨细胞瘤(T - GCT)和色素沉着绒毛结节性滑膜炎(PVNS)是滑膜组织罕见良性增生的可互换术语。尽管有人提出其起源为肿瘤性和炎症性,但这种疾病的病因尚不清楚。关于手术治疗存在争议,因为文献报道开放性滑膜切除术和关节镜下滑膜切除术的结果相当。然而,由于现有文献存在选择性偏倚且缺乏前瞻性随机对照试验,直接比较这两种手术方法存在问题。在膝关节后方,经切口从前侧入路观察该区域时,由于存在解剖盲区,关节镜下滑膜切除术在技术上具有挑战性。此外,关节镜下滑膜切除不完全会增加PVNS的复发率,因此必须切除整个病变。经间隔入路(TSP)技术利用后内侧和后外侧入路,通过分隔膝关节两个后间室的后间隔创建一个关节内入路。该入路允许操作器械在前后间隔之间来回通过,增加了对髁后上方滑膜衬里和后交叉韧带后方滑膜折返的可视化,从而能够对关节镜下PVNS切除术进行全面评估。在本视频文章中,我们描述了一种使用TSP对膝关节后间室PVNS进行关节镜后滑膜切除术的方法。
患者的体位应使对侧腿不会妨碍在后内侧入路进行操作。通过标准的前内侧和前外侧入路进行诊断性关节镜检查。接下来,在膝关节屈曲90°、从前外侧入路观察的情况下,使用透光的脊椎穿刺针创建后内侧入路。后外侧入路的创建方式与后内侧入路相同,从前内侧入路经切口观察。将关节镜置于后内侧入路时,可通过后外侧入路置入钝性器械或电动刨削器,以穿透后间隔并创建TSP。然后可识别肿块、进行活检,并使用电动刨削器或组织抓钳将其切除。随后可通过TSP进行关节镜探查以确认切除是否彻底。
替代方法包括通过切开手术进行滑膜切除术、经后内侧或后外侧入路并经切口观察进行关节镜检查,或两者结合。为了降低弥漫性PVNS复发的风险,有人描述了使用钇 - 90或磷 - 32进行放射性滑膜切除术,可与手术联合或单独使用。也有人使用了外照射,但辐射毒性被视为一个主要限制。巨噬细胞集落刺激因子(M - CSF)或CSF - 1抑制剂最近已被研发出来。2019年,美国食品药品监督管理局(FDA)批准了CSF - 1抑制剂的使用,它们被认为是不适于手术切除患者的一种可接受的治疗方法。
优点包括增加了后方解剖结构的可视化,以确保滑膜切除彻底,器械操作空间更大,与开放手术相比,减少了解剖层面的破坏以及神经血管结构周围瘢痕组织的形成。
对于PVNS滑膜切除术的TSP技术,已报道了出色的临床结果(定义为膝关节功能完全恢复)。在一项对10例通过使用TSP进行关节镜下滑膜切除术切除膝关节后方PVNS肿块的研究中,Shekhar等人报道了良好的功能结果且无手术并发症。Keyhani等人报道了一组21例接受相同手术治疗弥漫性PVNS的患者,结果相似。患者在接受该手术后有望保留接近完全的膝关节功能。建议所有患者在切除后3至6个月进行基线磁共振成像检查,因为可能会出现无症状复发,患者切除后应至少随访2年。
在创建后方入路时,将膝关节保持在屈曲90°可使内侧的大隐静脉、外侧的腓总神经以及后间隔附近的腘动脉距离最远。建议对后方入路进行透光观察。间隔的穿孔应从后外侧向后内侧方向进行,使外科医生有更宽的“安全区”,以降低腘动脉血管损伤的几率。
CSF = 集落刺激因子;MCL = 内侧副韧带;MRI = 磁共振成像;PL = 后外侧;PM = 后内侧;PA =腘动脉;ROM = 活动范围;TS = 经间隔;IKDC = 国际膝关节文献委员会